Posted by Michael Wonder on 24 May 2022
Nymox receives RTF letter from FDA
23 May 2022 - Nymox Pharmaceutical Corporation reports today that it has received a refusal to file letter from FDA on Friday 20 May at 2:48 pm EST, with regard to the Company's new drug application for Fexapotide Triflutate.
Nymox’s position is that clarifications remain to be resolved at a follow-up meeting and that some significant inconsistencies were involved.
